Trade Cassava Sciences Inc - SAVA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.64 |
| Open | 2.69 |
| 1-Year Change | -88.01% |
| Day's Range | 2.49 - 2.69 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 2.49 | -0.23 | -8.46% | 2.72 | 2.74 | 2.49 |
| Feb 20, 2025 | 2.64 | -0.07 | -2.58% | 2.71 | 2.78 | 2.62 |
| Feb 19, 2025 | 2.72 | 0.24 | 9.68% | 2.48 | 2.77 | 2.45 |
| Feb 18, 2025 | 2.50 | 0.14 | 5.93% | 2.36 | 2.53 | 2.36 |
| Feb 14, 2025 | 2.36 | 0.04 | 1.72% | 2.32 | 2.47 | 2.32 |
| Feb 13, 2025 | 2.32 | 0.05 | 2.20% | 2.27 | 2.32 | 2.22 |
| Feb 12, 2025 | 2.27 | 0.05 | 2.25% | 2.22 | 2.27 | 2.21 |
| Feb 11, 2025 | 2.25 | 0.03 | 1.35% | 2.22 | 2.29 | 2.21 |
| Feb 10, 2025 | 2.25 | 0.06 | 2.74% | 2.19 | 2.28 | 2.19 |
| Feb 7, 2025 | 2.21 | -0.07 | -3.07% | 2.28 | 2.31 | 2.19 |
| Feb 6, 2025 | 2.27 | -0.09 | -3.81% | 2.36 | 2.38 | 2.27 |
| Feb 5, 2025 | 2.37 | 0.04 | 1.72% | 2.33 | 2.43 | 2.25 |
| Feb 4, 2025 | 2.33 | 0.02 | 0.87% | 2.31 | 2.39 | 2.28 |
| Feb 3, 2025 | 2.30 | 0.13 | 5.99% | 2.17 | 2.32 | 2.17 |
| Jan 31, 2025 | 2.31 | 0.01 | 0.43% | 2.30 | 2.42 | 2.29 |
| Jan 30, 2025 | 2.32 | 0.05 | 2.20% | 2.27 | 2.34 | 2.25 |
| Jan 29, 2025 | 2.25 | -0.01 | -0.44% | 2.26 | 2.31 | 2.24 |
| Jan 28, 2025 | 2.30 | -0.12 | -4.96% | 2.42 | 2.42 | 2.28 |
| Jan 27, 2025 | 2.42 | 0.03 | 1.26% | 2.39 | 2.50 | 2.39 |
| Jan 24, 2025 | 2.45 | -0.03 | -1.21% | 2.48 | 2.60 | 2.41 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cassava Sciences Inc. Company profile
Cassava Science Inc is a clinical-stage biopharmaceutical company that specialises in detecting and treating Alzheimer’s disease, an incurable progressive neurologic disorder, which is . The company is listed on the Nasdaq under the ticker SAVA.
According to Cassava, over five million people in the US have Alzheimer’s. The company focuses on research and development to find new approaches for its treatment and diagnosis.
Cassava is developing Simufilam for the proposed treatment of Alzheimer's. According to the company, Simufilam is a proprietary oral drug candidate, developed in-house with academic collaborators. Simufilam, or PTI-125, is the company’s lead therapeutic product candidate. It’s currently (17 March) undergoing Phase 3 clinical studies.
SavaDx is the company’s investigational diagnostic for Alzheimer’s. According to the company, SavaDx is being developed to detect the disease with a simple blood test. However, SavaDx is still an early-stage product candidate and a lower priority than Simufilam, Cassava said.
Cassava was incorporated in 1998. It’s based in Austin, Texas, US. Remi Barbier has served as president, CEO and chairman of the board of directors since the company’s inception. Nadav Friedmann is the company’s chief medical officer. James Kupiec is the chief clinical development officer.
| Industry: | Bio Therapeutic Drugs |
6801 N Capital Of Texas Highway
Building 1; Suite 300
AUSTIN
TEXAS 78731
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com